The following is a summary of the Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Cue Biopharma reported collaboration revenue of approximately $1.8 million in Q4, primarily from the partnership with Ono Pharmaceuticals for CUE-401.

• Full-year collaboration revenues reached $5.5 million.

• Q4 research and development expenses were $10.9 million, a decrease from the previous year's Q4 expense of $11.3 million.

• General and administrative expenses for Q4 increased to $4.6 million.

• The company reported a year-end cash and cash equivalents balance of $48.5 million, sufficient to fund operations into the first quarter of 2025.

Business Progress:

• Cue Biopharma is making progress in developing treatments for cancer and autoimmune diseases, with clinical trials for products CUE-101 and CUE-102 showing promise.

• There has been significant progress with preclinical autoimmune programs, CUE-401 and the CUE-500 series.

• The company is aligning strategically with third parties to enhance development capabilities.

• Cue Biopharma has plans for a Phase 2 trial to confirm the CUE-101 dose, and currently enrolls patients in four indications for the expansion phase of the CUE-102 trial.

• Work is being done on advancing autoimmune disorder programs CUE-401 and CUE-500, with new data expected to be presented at the ASCO meeting in June.

• Future strategic partnerships are being sought to bolster growth and development.

• The company will determine two doses for their upcoming trial, and the final analysis from the trial data will lead to Phase 3 trials.

• Data on projects CUE101-01 and CUE-102 will be presented at the upcoming ASCO conference.

• Concentration also remains on autoimmune projects, with the intent to produce valuable data for future presentations.

More details: Cue Biopharma IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.